Boston Scientific Mexico (BSCI) organized the first Latin American Structural Cardiology Congress, bringing together more than 100 health experts from Mexico and Latin America to discuss cutting-edge treatments to treat cardiovascular diseases such as atrial fibrillation and aortic stenosis.
This congress is the first of its kind in Mérida and offers a hundred cardiologists or cardiologists with specialties such as interventionists, electrophysiologists, echocardiographers and others the opportunity to talk about therapies and how the implementation and solutions of this type of technologies contribute to improving the quality of life Of the patients.
“The focus of this meeting is to discuss and debate the innovative, cutting-edge therapies available to address conditions such as atrial fibrillation and aortic stenosis. Globally, the success rates of these treatments available at Boston Scientific are over 98-99%, restoring patients’ quality of life,” said Juan Aldrete, Head of Cardiology at Boston Scientific Mexico.
Atrial fibrillation is the most common form of cardiac arrhythmia worldwide. Experts indicate that the prevalence of this disease is 1.5 to 2% of the world’s population. The main feature is that blood stagnation occurs because the heart is not pumping properly.
It is considered the most debilitating incidence in the world because these patients are up to five times more likely to suffer a stroke or stroke due to the formation of blood clots.
Treatment consists of anticoagulants to thin the blood and prevent it from stagnating. However, patients with high blood pressure, diabetes, ulcers or bleeding in the digestive tract, among others, are contraindicated and require the most modern therapies.
On the other hand, aortic valve stenosis is characterized by thickening and hardening of the valves, mainly due to calcifications, obstructing blood flow.
Symptoms of aortic stenosis include heart failure, angina, or syncope (fainting). Once symptoms appear and appropriate treatment is not provided, approximately 50% of patients die within approximately 2 years. And 80% after five years.
The risk factors for aortic valve stenosis increase with age, with the prevalence being greater in men – eight out of 10 adults who suffer from it are male – those with high blood pressure, high cholesterol and smokers.
Boston Scientific’s cutting-edge therapies treat cardiovascular diseases such as atrial fibrillation and aortic stenosis, helping to improve patients’ quality of life.
“This space for discussions about therapies that currently have the greatest scientific evidence in the world encourages us to continue innovating and developing solutions that change patients’ lives and help healthcare professionals provide the best possible care,” concludes Juan Aldrete, director of the cardiology business unit of Boston Scientific Mexico.
